Hodgkin Variant of Richter’s Transformation: Is Transplant Always an Answer?

Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature

“…While hematopoietic stem‐cell transplantation (SCT) is a well‐established indication as postremission consolidation therapy for transplant‐eligible patients with DLBCL‐RT (especially for those with clonally related disease), the role of SCT, either autologous or allogeneic, is not well‐defined in HL‐RT. 13 , 25 , 26 , 27 Given the lack of data for SCT in HL‐RT patients who achieve a CR after first‐line therapy, these are typically observed until progression, with SCT being reserved for those eligible patients with relapsed/refractory disease. 27 …”

“… 13 , 25 , 26 , 27 Given the lack of data for SCT in HL‐RT patients who achieve a CR after first‐line therapy, these are typically observed until progression, with SCT being reserved for those eligible patients with relapsed/refractory disease. 27 …”

“…13,[25][26][27] Given the lack of data for SCT in HL-RT patients who achieve a CR after firstline therapy, these are typically observed until progression, with SCT being reserved for those eligible patients with relapsed/refractory disease. 27 In patients exposed to targeted CLL therapies (including BTK and BCL-2 inhibitors) or prior chemoimmunotherapies, the management of RT may benefit from the usage of novel agents (for example, checkpoint inhibitors), which have shown promising results in multiple studies. 4,28,29 However, further data on the role of moleculartargeted therapies are needed.…”

“…6 While hematopoietic stem-cell transplantation (SCT) is a well-established indication as postremission consolidation therapy for transplant-eligible patients with DLBCL-RT (especially for those with clonally related disease), the role of SCT, either autologous or allogeneic, is not well-defined in HL-RT. 13,[25][26][27] Given the lack of data for SCT in HL-RT patients who achieve a CR after firstline therapy, these are typically observed until progression, with SCT being reserved for those eligible patients with relapsed/refractory disease. 27 In patients exposed to targeted CLL therapies (including BTK and BCL-2 inhibitors) or prior chemoimmunotherapies, the management of RT may benefit from the usage of novel agents (for example, checkpoint inhibitors), which have shown promising results in multiple studies.…”